To the Editor: We believe that an important myositis-associated autoantibody, which could be of interest in the differential diagnosis, was overlooked by Drs. Korn and Mauiyyedi in their discussion of ...

Please provide your email address to receive an email when new articles are posted on . Autoimmune diseases may be easier to treat than cancers using cell therapy. Studies continue to examine its use ...

– 7 of 8 myositis patients achieved clinically meaningful TIS responses after discontinuation of all immunomodulators, while off or actively tapering steroids; responses were sustained throughout the ...

An investigative synthetic cannabinoid receptor type 2 (CB2) agonist, lenabasum, was associated with greater improvements than placebo in patients with skin-predominant dermatomyositis — some of it ...

Cabaletta Bio, Inc. announced promising results from its ongoing RESET clinical trials for its investigational therapy rese-cel, focusing on autoimmune diseases. In the trials, notable outcomes ...